Dimon Steps Down as JPMorgan (JPM) Bank Chairman

Jacob Harper |

JPMorgan & Chase Co (JPM) CEO Jamie Dimon has relinquished his role as chairman of the bank’s main subsidiary following a tumultuous year as its head.

Dimon first came to prominence as one of the few cool heads in the 2008 banking crisis, as JPMorgan avoided the catastrophic losses to which every other major financial institution fell prey. However, after several years as the posterboy of restraint and accountability, Dimon did a 180, and has become the go-to for stories concerning financial impropriety and unethical business practices.

While several scandals have rocked the bank, the most notable is probably the “London Whale” trade debacle, wherein the London branch of JPMorgan realized $6.2 billion in losses during the summer of 2012. While the losses themselves were obviously a problem, Dimon’s handling of the London Whale was what really took the sheen off of his previously impeccable leadership.

Dimon was criticized vehemently for withholding documents from investigators during ongoing investigations into the London Whale. But more infuriating to the public and investors than his lack of cooperation during the investigation was his flippant attitude.

Dimon infamously referred to the loss and resulting fervor and cover-up as a “tempest in a teapot” which, along with general sentiment the bank had put stockholder’s investments in jeopardy by failing to handle the situation correctly, spurred a coup against him and the JPMorgan itself, and led to an attempt to oust him from his leadership role and break up the bank.

That coup was crushed when a vote retained Dimon as CEO and chairman, although his pay had already been slashed in half as punishment.

Aside from the Whale scandal, which cost the bank $920 million in settlements just two weeks prior, JPMorgan has been embroiled in far reaching scandals ranging from bribing Chinese regulators to engaging in commodity price fixing.

JPMorgan’s attorneys claim Dimon is stepping down for technical reasons, and not because of any governmental pressure to minimize his position in the company.   

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Spotlight

BiondVax Pharmaceuticals Ltd.

Biondvax Pharmaceuticals Ltd Ltd is a clinical stage biopharmaceutical company. The Company is engaged in developing, manufacturing and commercializing immunomodulation therapies for infectious diseases.

Events

EQUITIES Emerging Growth and Innovation Forum

EQUITIES Inaugural Emerging Growth and Innovation Forum at Disruptive firm MRY New York City's Flatiron District. The forum is on February 24th from 12:00 pm to 6:00 pm with a…

Learn more

Research

MagneGas Corporation (MNGA)

MagneGas Corporation is an alternative energy company that creates a system that produces hydrogen based fuel through the gasification and sterilization of liquid and liquid waste. ($49 USD)

Learn more

Private Markets

SU Labs Accelerator Seed Fund

We're a fiercely passionate community of entrepreneurs leveraging rapidly accelerating technologies to create a brighter future. Join us in fostering innovation, driving impact and funding the future.

FAB Financial Inc.

Banking is broken. Years ago people who needed business advice would turn to their local bank manager for help. The banker was thought of as a trusted member of the…